A/S Toldbodgade 33 1253 K Tel + 45 7020 2728 Fax + 45 7020 2729 CVR no. 2102 3884 Contact:

Tatiana Brask Director IR&PR T: +45 33 44 77 26 M: +45 25 40 30 39 E: [email protected]

GENMAB A/S SUMMONS EXTRAORDINARY GENERAL MEETING

Summary: Genmab to hold Extraordinary General Meeting on November 11, 2003 to elect a new member of the Board of Directors.

Copenhagen, Denmark; October 20, 2003 – Genmab A/S (CSE: GEN) will hold an Extraordinary General Meeting on Tuesday November 11, 2003 at 4:00 pm at the Scandic Hotel Copenhagen, Vester Søgade 6, 1601 Copenhagen V, Denmark.

The purpose of the Extraordinary General Meeting and sole item on the agenda is the proposed election of a new member of the Board of Directors.

The Board of Directors proposes the election of Dr. Anders Gersel Pedersen, who if elected, will bring the number of members of Genmab A/S’s Board of Directors to a total of six.

Dr. Pedersen (age 52) is Senior Vice President, Development at H. A/S, Denmark. Following his degree in medicine and Research Fellow positions at Copenhagen hospitals, Dr. Pedersen worked for Eli Lilly for eleven years; ten of these as a director overseeing world-wide clinical research in oncology, before joining Lundbeck in 2000. At Lundbeck Dr. Pedersen is responsible for the development of the product pipeline including the clinical research. He is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine and serves on the board of TopoTarget A/S. Dr. Pedersen received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a BSc in Business Administration from the Copenhagen Business School.

Admission card: Any shareholder is entitled to attend the Extraordinary General Meeting after having submitted a request for an admission card no later than November 6, 2003.

1/2 Release no. 35/2003 GENMAB A/S SUMMONS EXTRAORDINARY GENERAL MEETING

Any shareholder, to whom an admission card already has been issued, who is unable to attend the Extraordinary General Meeting is kindly asked to notify the Company no later than November 6, 2003.

About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.’s array of proprietary technologies, including the UltiMAb™ platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark and has operations in Utrecht, The and Princeton, New Jersey in the US. For more information about Genmab, visit www.genmab.com.

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects.

Statements that are not historical facts, including statements preceded by, followed by, or that include the words “believes”; “anticipates”; “plans”; “expects”; “estimates”; or similar statements are forward-looking statements. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

###

2/2